List of Excipients in Branded Drug RISVAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Laboratorios Farmaceuticos Rovi SA	RISVAN	risperidone	82090-003	DIMETHYL SULFOXIDE
Laboratorios Farmaceuticos Rovi SA	RISVAN	risperidone	82090-003	POLY(DL-LACTIC-CO-GLYCOLIC ACID)

RISVAN Excipient Strategy and Commercial Opportunities: Formulation, Patent Risk, and Generic Competition

Last updated: September 24, 2026

RISVAN is a long-acting risperidone injectable based on a prolonged-release microsphere formulation. Its commercial value depends on sustained drug release, reproducible particle engineering, sterile suspension stability, and a delivery system that can support outpatient administration. The strongest excipient opportunities are in medical-grade biodegradable polymers, suspension vehicles, lyophilized-powder processing, sterile diluents, and manufacturing controls rather than in conventional tablet excipients.

Publicly available information identifies RISVAN with Luye Pharma’s long-acting risperidone product family. Product names, approved strengths, and regulatory status vary by market. RISVAN should be distinguished from Risperdal Consta, Okedi, UZEDY, and Rykindo because each uses a different release platform, manufacturing process, or commercial jurisdiction.

What is RISVAN and how does its formulation work?

RISVAN is a prolonged-release injectable form of risperidone intended to reduce daily oral dosing and improve adherence in schizophrenia treatment. The formulation is based on drug-loaded biodegradable microspheres, generally using a poly(lactide-co-glycolide), or PLGA, matrix.

The microspheres are administered by intramuscular injection. After injection, the polymer matrix hydrates and gradually erodes. Risperidone diffuses from the particles and is released as the polymer undergoes hydrolysis.

Product characteristic	RISVAN formulation profile
Active ingredient	Risperidone
Dosage form	Prolonged-release injectable microsphere suspension
Route	Intramuscular injection
Release technology	Biodegradable polymer microspheres
Primary polymer class	PLGA or related aliphatic polyester
Commercial objective	Extended exposure with reduced dosing frequency
Key quality attributes	Particle size, drug loading, residual solvent, release profile, sterility, syringeability
Primary manufacturing risk	Batch-to-batch control of microsphere morphology and release kinetics

The excipient system is not a simple vehicle. It controls the injectable’s dose uniformity, reconstitution behavior, sedimentation, syringe force, injection-site performance, and pharmacokinetic profile.

What excipients are likely to be used in RISVAN?

The formulation strategy is likely to include a biodegradable polymer matrix, a suspension medium, a wetting or dispersion aid, and a sterile diluent or reconstitution system. Exact quantitative composition should be taken from the applicable national product information and regulatory filing.

PLGA polymer

PLGA is the central excipient in a risperidone microsphere product. Its commercial value derives from control over:

• Lactide-to-glycolide ratio.
• Polymer molecular weight.
• End-group chemistry.
• Intrinsic viscosity.
• Particle porosity.
• Residual monomer and solvent.
• Glass-transition temperature.
• Hydrolysis rate.

Higher glycolide content generally accelerates polymer hydration and degradation. Higher molecular weight and greater lactide content generally support slower degradation, although release also depends on particle size, drug loading, porosity, and manufacturing conditions.

For RISVAN, polymer suppliers with pharmaceutical-grade PLGA, consistent lot-to-lot molecular-weight distribution, low endotoxin levels, and validated extractables profiles have a higher commercial position than suppliers offering commodity polymer grades.

Suspension vehicle

The vehicle must keep microspheres evenly dispersed long enough to permit dose withdrawal and injection. Likely functional categories include:

• Water for injection.
• Isotonicity agents such as sodium chloride.
• Buffering agents.
• Surfactants or wetting agents.
• Suspending agents.
• Osmolality and pH adjusters.

The vehicle must not accelerate PLGA hydrolysis before administration. Buffer selection is therefore a technical and regulatory issue. Aqueous systems with unfavorable pH, excessive ionic strength, or reactive excipients can alter polymer degradation and risperidone release.

Surfactants and wetting agents

A low concentration of a nonionic surfactant can reduce particle aggregation and improve wetting. Candidate classes include polysorbates and poloxamers, subject to compatibility and extractables testing.

The commercial opportunity is concentrated in high-purity, low-peroxide grades. Oxidative impurities in surfactants can affect drug stability, polymer integrity, and container closure performance. Suppliers able to provide controlled peroxide levels, low particulate burden, and injectable-grade documentation can command premium pricing.

Suspending agents

Suspending agents may improve dose uniformity but can increase viscosity and injection force. Cellulosic polymers, povidone, or other water-soluble materials may be considered during development, but their use is constrained by:

• Needle gauge.
• Reconstitution time.
• Sedimentation rate.
• Redispersibility.
• Injection force.
• Sterilization compatibility.
• Local tolerability.

The preferred commercial formulation is not necessarily the most viscous formulation. A low-viscosity system with controlled sedimentation is more compatible with standard clinical injection practices.

What formulation attributes create the greatest commercial opportunity?

The largest opportunity is in excipient systems that improve administration without materially changing risperidone release. Four technical targets are commercially relevant.

Faster reconstitution

Microsphere products can require mixing or reconstitution before injection. Suppliers can compete through excipient systems that shorten wetting time, reduce clumping, and improve redispersion.

A product that reduces preparation time can lower administration burden for psychiatric clinics and specialty pharmacies. The improvement must preserve dose uniformity and release kinetics.

Lower injection force

Large-particle suspensions and viscous vehicles can require greater injection force. This creates a market for:

• Narrower particle-size distributions.
• Controlled particle morphology.
• Lower-viscosity vehicles.
• Optimized surfactant systems.
• Prefilled syringe configurations.
• Needle-compatible suspension systems.

Injection-force data are likely to become more important as manufacturers pursue smaller needles, self-administration models, and home-based treatment.

Improved storage stability

PLGA microspheres are sensitive to moisture and temperature. Commercially useful improvements include:

• Lower residual moisture.
• Better moisture-barrier packaging.
• Stabilized lyophilized powders.
• Improved polymer end-group control.
• Reduced aggregation during storage.
• More robust reconstitution after transport.

Packaging suppliers and excipient manufacturers can capture value if they demonstrate extended shelf life without changing the in vitro release profile.

Reduced dose variability

The microsphere suspension must deliver a consistent amount of risperidone despite settling. Particle-size engineering, density matching, controlled viscosity, and optimized redispersion can reduce dose variability.

A formulation change that improves dose uniformity may have greater regulatory value than a small reduction in raw-material cost because it can improve process capability and reduce batch failures.

How does RISVAN compare with other long-acting risperidone products?

RISVAN competes in a fragmented long-acting antipsychotic market. The key distinction is delivery technology.

Product	Active ingredient	Release platform	Commercial distinction
RISVAN	Risperidone	Prolonged-release microspheres	Polymer-based depot suspension
Risperdal Consta	Risperidone	PLGA microspheres	Established long-acting reference product
Okedi	Risperidone	In situ forming depot technology	Different manufacturing and administration model
UZEDY	Risperidone	Extended-release subcutaneous suspension	Subcutaneous delivery and proprietary formulation
Rykindo	Risperidone	Extended-release microspheres	Luye Pharma product family in selected markets
Perseris	Risperidone	Subcutaneous in situ depot	Different excipient and administration platform

The comparison matters for excipient suppliers. RISVAN and Risperdal Consta may share broad polymer concepts, but their specific polymer grades, particle engineering, release-control methods, and suspension systems may differ. Okedi, UZEDY, and Perseris create alternative opportunities in in situ gels, injectable suspensions, and delivery-device systems.

What patents protect RISVAN’s excipient and manufacturing strategy?

Protection for a microsphere product is usually distributed across several patent categories rather than one composition patent.

Formulation patents

Potential claim categories include:

• Risperidone-loaded PLGA microspheres.
• Specific lactide-to-glycolide ratios.
• Defined polymer molecular-weight ranges.
• Drug-loading percentages.
• Particle-size distributions.
• Porosity or morphology parameters.
• Release profiles over specified time periods.
• Specific suspension vehicles.
• Reconstitution systems.
• Injectable dose strengths.

Manufacturing patents

Manufacturing claims may cover:

• Emulsion-solvent evaporation.
• Spray drying.
• Microfluidic particle production.
• Solvent extraction.
• Freeze-drying of microspheres.
• Organic-solvent removal.
• Sterile filtration of process streams.
• Particle-size classification.
• In-process release testing.

Method-of-use patents

Risperidone’s core therapeutic use is old, but later patents can claim:

• Dosing intervals.
• Conversion from oral risperidone.
• Initiation regimens.
• Treatment of specific patient populations.
• Adherence-related treatment methods.
• Administration by a particular route or device.

Method-of-use claims are generally more vulnerable to physician-instruction and label-based design-around issues than formulation or manufacturing claims.

Patent strength

The strongest protection is usually a combination of composition, process, and performance claims. A claim directed only to PLGA microspheres containing risperidone may face prior-art pressure because long-acting risperidone microspheres are an established technology. Narrow claims tied to defined release kinetics, polymer specifications, particle morphology, or manufacturing controls may be more defensible if supported by unexpected performance.

When does RISVAN lose exclusivity?

RISVAN exclusivity must be assessed separately by country because patent filings, regulatory approvals, supplementary protection rights, and data exclusivity differ across jurisdictions.

A commercial review should identify:

1. The first approved RISVAN product in each market.
2. The applicable composition-of-matter, formulation, process, and use patents.
3. Patent-term adjustments or supplementary protection certificates.
4. Regulatory data exclusivity.
5. Pending patent applications and continuations.
6. Any settlement or license agreements.
7. Orange Book or equivalent patent listings, where applicable.

RISVAN is not automatically protected by the patent estate for Risperdal Consta. The relevant question is whether the same formulation, manufacturing process, or delivery system is claimed in an enforceable patent.

What is the Orange Book status of RISVAN?

The FDA Orange Book status depends on the exact U.S. product and applicant name. RISVAN should not be treated as Orange Book-listed merely because a related risperidone injectable is approved elsewhere.

For U.S. diligence, analysts should separate:

• FDA approval of the specific RISVAN-branded product.
• Approval of a Luye-affiliated risperidone microsphere product under another brand.
• Orange Book-listed patents.
• Patent certifications submitted by abbreviated new drug applicants.
• Reference-listed-drug status.
• Any 505(b)(2) pathway used by a competing product.

If the product is not an FDA reference-listed drug, a conventional ANDA pathway may not be available for a directly substitutable generic. A 505(b)(2) applicant may instead need to address clinical, pharmacokinetic, device, or formulation differences.

Which companies may challenge RISVAN?

Potential challengers fall into four groups:

Challenger type	Likely strategy
Generic injectable manufacturers	Develop a microsphere formulation with an ANDA or hybrid pathway
Specialty injectable companies	Use a 505(b)(2) or national hybrid application
Long-acting antipsychotic developers	Compete with alternative risperidone or paliperidone delivery systems
Excipient and CDMO partners	Enable non-infringing polymer, vehicle, or manufacturing processes

A Paragraph IV challenge is possible only where the product has a U.S. reference product and listed patents eligible for certification. The key barriers are not limited to patent claims. A challenger must reproduce the release profile, demonstrate bioequivalence or clinical comparability, manage sterile manufacturing, and establish acceptable injection performance.

What generic-entry risks exist for RISVAN?

Generic entry is technically more difficult than entry for an oral risperidone tablet. The major barriers are:

• Complex microsphere manufacturing.
• Long in vitro release testing.
• Difficult in vivo-in vitro correlation.
• Limited tolerance for particle-size differences.
• Sterility and endotoxin controls.
• Residual solvent limits.
• Reconstitution and syringeability requirements.
• Potentially different pharmacokinetic tail behavior.
• Limited availability of suitable reference batches.

A successful generic may use a different polymer grade or process if it can demonstrate equivalent clinical performance without infringing valid claims. The most exposed claims are broad claims to risperidone microspheres. Narrow process claims may be easier to design around but can still create manufacturing uncertainty.

What licensing deals and partnerships are commercially relevant?

The most valuable partnership targets are:

• PLGA suppliers with injectable-grade polymer platforms.
• Contract development and manufacturing organizations with microsphere capability.
• Sterile fill-finish manufacturers.
• Prefilled syringe and dual-chamber device companies.
• Specialty distributors serving psychiatric clinics.
• Regional licensees with depot-injection infrastructure.

Luye Pharma’s commercial strategy has included regional development and commercialization of long-acting risperidone products. Any diligence should distinguish product licensing from manufacturing supply agreements. A supply agreement may create practical dependence on a polymer or fill-finish partner without granting that partner rights to the underlying drug technology.

How can excipient suppliers capture value from RISVAN?

The best opportunities are differentiated, regulatory-ready products rather than low-cost commodity excipients.

High-value supply opportunities

• Pharmaceutical-grade PLGA with tight molecular-weight specifications.
• Low-peroxide polysorbate or poloxamer grades.
• Sterile or low-bioburden suspension vehicles.
• Moisture-barrier vials and prefilled syringe components.
• Validated residual-solvent testing.
• Particle-size and morphology analytics.
• Release-testing services.
• Scale-up and tech-transfer support.
• Alternative polymers that enable non-infringing follow-on products.

Commercial model

Suppliers can pursue three models:

1. Direct excipient supply under a quality agreement.
2. Co-development with formulation ownership allocated by contract.
3. Platform licensing for polymer grades, particle engineering, or device integration.

The third model has the highest margin but also carries the greatest freedom-to-operate risk. A supplier that contributes a novel polymer specification or particle-engineering method should document ownership, background technology, improvements, and use restrictions before scale-up.

Key Takeaways

• RISVAN is a long-acting risperidone microsphere product associated with Luye Pharma’s injectable portfolio.
• PLGA or a related biodegradable polyester is the principal release-controlling excipient.
• Commercial differentiation depends on reconstitution speed, injection force, suspension stability, particle uniformity, and shelf life.
• The most attractive excipient opportunities are injectable-grade PLGA, controlled surfactants, suspension vehicles, moisture-barrier packaging, and analytical services.
• Patent protection may extend across formulation, particle morphology, manufacturing, dosing, and administration methods.
• Generic entry is more difficult than for oral risperidone because bioequivalence, release testing, sterility, and injection performance must be controlled together.
• RISVAN’s Orange Book position must be assessed by the specific U.S. product and applicant; related risperidone depot products cannot be substituted for that analysis.
• Alternative long-acting risperidone technologies, including in situ depots and subcutaneous systems, are direct competitive threats.

FAQs

Is PLGA the only viable excipient for a RISVAN follow-on product?

No. A follow-on product could use another biodegradable polyester or a different depot technology, but it would likely face a more complex regulatory pathway and greater clinical comparability requirements.

Can a generic manufacturer use a different PLGA supplier?

Yes, if the alternative grade delivers equivalent critical quality attributes and does not infringe enforceable formulation or process claims. Molecular weight, end-group chemistry, residual solvent, and degradation behavior would require close control.

Are RISVAN and Risperdal Consta interchangeable?

Not automatically. Both are long-acting risperidone products, but their approved dosing, release systems, administration requirements, and regulatory labeling must be evaluated separately.

What is the most valuable excipient improvement for RISVAN?

A formulation that improves redispersion and lowers injection force while preserving the approved release profile is likely to have the strongest commercial value.

Can an excipient supplier patent a RISVAN improvement?

Potentially. Patentable subject matter may include a novel polymer specification, stabilizer combination, suspension vehicle, particle morphology, manufacturing process, or packaging system, subject to novelty, inventive step, enablement, and freedom-to-operate analysis.

References

1. European Medicines Agency. (n.d.). Risperidone-containing medicines and European public assessment information. EMA.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.

4. Luye Pharma Group Ltd. (2024). Annual report and long-acting injectable antipsychotic product information. Luye Pharma.

5. U.S. Food and Drug Administration. (2023). Risperdal Consta prescribing information. FDA.

6. U.S. Food and Drug Administration. (2023). UZEDY prescribing information. FDA.

7. European Medicines Agency. (2022). Guideline on the quality of oral modified-release products and parenteral depot formulations. EMA.

8. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia. EDQM.